everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...7891011121314151617...132133»
  • ||||||||||  cyclophosphamide / Generic mfg., everolimus / Generic mfg., mesna / Generic mfg.
    Enrollment closed:  LITMMUS-MGH: Liver Transplantation With Tregs at MGH (clinicaltrials.gov) -  Sep 21, 2023   
    P1/2,  N=9, Active, not recruiting, 
    Recruiting --> Active, not recruiting
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Asymptomatic course of rhabdomyoma of the heart (Pubmed Central) -  Sep 15, 2023   
    The case is of interest for a long asymptomatic growth of rhabdomyoma. Generally, cardiac rhabdomyomas are diagnosed in the postnatal period and may be the earliest manifestation of tuberous sclerosis.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date, Combination therapy:  Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL (clinicaltrials.gov) -  Sep 13, 2023   
    P1,  N=45, Active, not recruiting, 
    Generally, cardiac rhabdomyomas are diagnosed in the postnatal period and may be the earliest manifestation of tuberous sclerosis. Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
  • ||||||||||  polyTregs / National Institute of Allergy and Infectious Diseases
    Trial completion:  TASK: Treg Therapy in Subclinical Inflammation in Kidney Transplantation (clinicaltrials.gov) -  Sep 13, 2023   
    P1/2,  N=14, Completed, 
    Trial completion date: Aug 2023 --> Dec 2023 Active, not recruiting --> Completed
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Paradigm shift in the treatment of tuberous sclerosis: effectiveness of everolimus. (Pubmed Central) -  Sep 11, 2023   
    Everolimus, a mammalian target of the rapamycin inhibitor, is able to reduce hamartomas, correcting the specific molecular defect that causes Tuberous sclerosis complex. In this review, we report the findings from the literature on the use of everolimus as an effective and safe drug in the treatment of TSC manifestations affecting various organs, from the central nervous system to the heart.
  • ||||||||||  everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
    Trial completion date, Post-transplantation:  TEAMMATE: Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score (clinicaltrials.gov) -  Sep 11, 2023   
    P3,  N=211, Active, not recruiting, 
    In this review, we report the findings from the literature on the use of everolimus as an effective and safe drug in the treatment of TSC manifestations affecting various organs, from the central nervous system to the heart. Trial completion date: May 2023 --> Jan 2024
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal, Metastases:  Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report. (Pubmed Central) -  Sep 8, 2023   
    Generally, survival is better; however, its treatment is challenging, and primary debulking surgery is often required. A team approach to management is important at all points.
  • ||||||||||  everolimus / Generic mfg.
    Enrollment open:  PREPARE-iVAC Trial (clinicaltrials.gov) -  Sep 6, 2023   
    P4,  N=110, Recruiting, 
    Initiation date: Sep 2023 --> Dec 2023 Not yet recruiting --> Recruiting
  • ||||||||||  everolimus / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Analysis of Circulating Tumor Markers in the Blood (ALCINA) (clinicaltrials.gov) -  Sep 6, 2023   
    P=N/A,  N=682, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Sep 2025 | Trial primary completion date: Jul 2023 --> Sep 2024
  • ||||||||||  AZD8055 / AstraZeneca
    Journal:  MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer. (Pubmed Central) -  Sep 2, 2023   
    Notably, MYC status was significantly associated with poor response to everolimus therapy in metastatic breast cancer patients. Thus, MYC is a clinically relevant driver of mTORi resistance that may stratify breast cancer patients for mTOR-targeted therapies.
  • ||||||||||  everolimus / Generic mfg.
    Biomarker, Retrospective data, Journal, Next-generation sequencing:  Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis. (Pubmed Central) -  Sep 1, 2023   
    The secondary endpoints were to decipher the mutation types across breast cancer subtype, menopausal status, and time to treatment failure after everolimus (an mTOR inhibitor) or cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment...A high frequency of PIK3CA mutations was detected in Taiwanese patients with breast cancer, which was consistent with previous studies. Early detection of PIK3CA mutations might influence therapeutic decisions, leading to better treatment outcomes.
  • ||||||||||  Journal:  Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022. (Pubmed Central) -  Aug 31, 2023   
    By analyzing the results of bibliometrics, national and international researchers can better understand the current research status of RCC immunotherapy and identify new directions for future research. However, the analysis also identified pockets of insularity, highlighting a need for greater collaboration and cooperation among researchers to advance the field of RCC immunotherapy.
  • ||||||||||  Undifferentiated pleomorphic sarcoma and atypical fibroxanthoma  (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_3282;    
    Histopathological examination presents hyperchromatic, pleomorphic, fusiform, and multinucleated cells. In UPS, involvement of the subcutaneous tissue, tumor necrosis, lymphovascular and perineural invasion has been observed, demonstrating a more aggressive character.
  • ||||||||||  aspirin / Generic mfg., everolimus / Generic mfg.
    Kasabach-Merritt phenomenon: a single center experience (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2456;    
    This phenomenon pathophysiology is still unknown making it a real diagnostic and therapeutic challenge. Inhibitors of the mammalian target of rapamycin (mTOR), Sirolimus and Everolimus , have been used since 2010 and are a promising therapy in the management of KMP, these medications can inhibit lymphangiogenesis and angiogenesis and have demonstrated their efficacy and safety .
  • ||||||||||  everolimus / Generic mfg.
    Prevalence of everolimus-induced isolated eyelid edema in a study population of 308 solid organ transplant patients (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2368;    
    In our study, we thoroughly investigated and ruled out potential causes of eyelid edema such as renal dysfunction, liver dysfunction, thyroid dysfunction, autoimmune diseases, complement deficiencies, hypersensitivity disorders, infectious states, and iatrogenic procedures. After conducting an accurate pharmacological history, we ruled out medications that could potentially cause eyelid edema, including angioedema induced by ACE inhibitors.
  • ||||||||||  sirolimus / Generic mfg.
    Sirolimus-induced DRESS syndrome (e-Poster Hall) -  Aug 30, 2023 - Abstract #EADV2023EADV_2362;    
    And since sirolimus and everolimus, both mTOR inhibitors, share a common mechanism of action, therapeutic indications, pharmacokinetics, adverse effects and drug interactions, it cannot be ruled out that sirolimus may trigger DRESS syndrome in patients with risk factors. In our case, the patient
  • ||||||||||  lapatinib / Generic mfg., everolimus / Generic mfg.
    Preclinical, Journal:  Proteomic Dynamics of Breast Cancer Cell Lines Identifies Potential Therapeutic Protein Targets. (Pubmed Central) -  Aug 28, 2023   
    In TNBC, metabolism pathways were dysregulated after EGFR/mTOR inhibitor treatment, while RNA modification and cell cycle pathways were affected by AKT inhibitor. This systematic multi-omics and in-depth analysis of the proteome of BC cells can help prioritize potential therapeutic targets and provides insights into adaptive resistance in TNBC.
  • ||||||||||  camizestrant (AZD9833) / AstraZeneca
    Trial completion date, Trial primary completion date, Metastases:  SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) -  Aug 28, 2023   
    P1,  N=403, Recruiting, 
    This systematic multi-omics and in-depth analysis of the proteome of BC cells can help prioritize potential therapeutic targets and provides insights into adaptive resistance in TNBC. Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: May 2024 --> Aug 2024
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Metastases:  Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) -  Aug 24, 2023   
    P1,  N=11, Active, not recruiting, 
    The newly identified ERV signature is not only a prognostic, but also a predictive biomarker for advanced ccRCC patients who received anti-PD-1 therapy, which can guide personalized treatment in cancer patients in the future. Recruiting --> Active, not recruiting
  • ||||||||||  everolimus / Generic mfg., mycophenolate mofetil / Generic mfg.
    Trial completion date, Trial primary completion date:  BK EVER: Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia. (clinicaltrials.gov) -  Aug 21, 2023   
    P4,  N=130, Active, not recruiting, 
    Antiangiogenic agents (sunitinib, regorafenib, pazopanib, axitinib) and the third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib exhibited modest anti-proliferative activity in the cell line, with IC50 values between 1 and 10 Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Sep 2022 --> Nov 2023
  • ||||||||||  Piqray (alpelisib) / Novartis, Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Review, Journal:  A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm. (Pubmed Central) -  Aug 21, 2023   
    The HER2-low expression has emerged as a targetable biomarker, and anti-HER2 antibody-drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2-low breast cancer (BC)...Although there are different therapeutic agents for hormone receptor-positive and hormone receptor-negative HER2-low BCs, there is no consensus regarding the sequencing of these agents. In this article, the treatment options for HER2-low BC are enumerated and a treatment sequencing algorithm based on the current clinical evidence proposed.
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  Conversion between sirolimus and everolimus in heart transplant recipients. (Pubmed Central) -  Aug 17, 2023   
    The conversion ratio of 1:2 observed in our population suggests OHT recipients may require an increased dose of EVL compared with SRL to maintain the same goal trough levels. A conversion between mTORi appeared to improve tolerability and did not lead to clinically significant worsening of any measured lab value.
  • ||||||||||  vepdegestrant (ARV-471) / Arvinas, Pfizer
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  TACTIVE-E: ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (clinicaltrials.gov) -  Aug 15, 2023   
    P1b,  N=32, Recruiting, 
    A conversion between mTORi appeared to improve tolerability and did not lead to clinically significant worsening of any measured lab value. Trial completion date: Feb 2024 --> Nov 2024 | Trial primary completion date: Aug 2023 --> May 2024
  • ||||||||||  metformin / Generic mfg., everolimus / Generic mfg.
    Journal, PD(L)-1 Biomarker, IO biomarker:  mTORC1 inhibition may improve T lymphocytes affected by aging. (Pubmed Central) -  Aug 15, 2023   
    However, the effect of both drugs on the T cells of young mice wasn't significant or was in opposite to the results of old mice T cells. In line with studies noting mTOR inhibitors as antiaging drugs, Metformin and Everolimus may improve T cells affected from aging in vitro, and a decrease in intracellular oxidative stress may be one of their mechanism of function.
  • ||||||||||  everolimus / Generic mfg.
    Journal:  PHF8-GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma. (Pubmed Central) -  Aug 6, 2023   
    Pharmacological inhibition of GLUL by l-methionine sulfoximine not only repressed ccRCC lipid deposition and tumor growth but also enhanced the anticancer effects of everolimus. Thus, the PHF8-GLUL axis represents a potential therapeutic target for ccRCC treatment.